Kodiak Sciences (NASDAQ:KOD) Price Target Raised to $145.00

Posted by Brenda Bartman on Oct 1st, 2026

Kodiak Sciences (NASDAQ:KOD – Free Report) had its price objective increased by Lifesci Capital from $85.00 to $145.00 in a report published on Monday,Benzinga reports. The firm currently has an outperform rating on the stock.

KOD has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Wall Street Zen lowered shares of Kodiak Sciences from a “sell” rating to a “strong sell” rating in a report on Saturday, September 26th. The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research report on Thursday, September 24th. They set a “neutral” rating and a $36.00 price objective on the stock. HC Wainwright boosted their target price on shares of Kodiak Sciences from $58.00 to $96.00 and gave the stock a “buy” rating in a report on Monday. Finally, UBS Group boosted their target price on shares of Kodiak Sciences from $80.00 to $120.00 and gave the stock a “buy” rating in a report on Monday. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $100.43.

Get Our Latest Research Report on KOD

Kodiak Sciences Stock Up 4.0%

NASDAQ:KOD opened at $94.80 on Monday. The business’s 50-day simple moving average is $41.32 and its two-hundred day simple moving average is $38.77. Kodiak Sciences has a 52 week low of $10.94 and a 52 week high of $98.80. The stock has a market cap of $5.96 billion, a PE ratio of -22.63 and a beta of 2.18.

Kodiak Sciences (NASDAQ:KOD – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09). Sell-side analysts anticipate that Kodiak Sciences will post -3.89 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 807,840 shares of the company’s stock in a transaction on Monday, September 28th. The stock was acquired at an average cost of $72.57 per share, with a total value of $58,624,948.80. Following the purchase, the director directly owned 19,121,134 shares of the company’s stock, valued at approximately $1,387,620,694.38. This represents a 4.41% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have acquired a total of 1,941,755 shares of company stock worth $156,986,026 in the last three months. 44.40% of the stock is owned by company insiders.

Institutional Trading of Kodiak Sciences

Several hedge funds have recently made changes to their positions in the business. Arizona State Retirement System lifted its holdings in shares of Kodiak Sciences by 6.9% in the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock valued at $332,000 after acquiring an additional 554 shares during the last quarter. V Square Quantitative Management LLC bought a new stake in Kodiak Sciences during the first quarter worth approximately $26,000. Westfuller Advisors LLC bought a new stake in Kodiak Sciences during the first quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its position in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after purchasing an additional 916 shares during the period. Finally, KBC Group NV purchased a new stake in Kodiak Sciences during the first quarter valued at approximately $39,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

Positive Sentiment: Strong Phase 3 results drive investor enthusiasm. Zenkuda and KSI-501 reportedly achieved their primary goals in the DAYBREAK study for wet age-related macular degeneration, meeting key endpoints against Eylea. Kodiak is advancing Zenkuda toward a biologics license application (BLA), creating a potential path toward regulatory review in a large retinal-drug market. Zenkuda positive wet AMD data article
Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm lifted its FY2029 EPS forecast to $1.76 from $0.18 and its FY2030 forecast to $5.81 from $3.04. It maintained a Buy rating and a $96 price target, while projecting a transition from losses in FY2027 and FY2028 to profitability in FY2029. Kodiak Sciences analyst estimates
Positive Sentiment: Insider purchases provide a confidence signal. Director Bros. Advisors LP Baker reported multiple purchases totaling roughly 1.94 million shares for approximately $157 million across September 28–29. The buying materially increased the director’s already substantial ownership stake. SEC insider ownership filing
Neutral Sentiment: Near-term analyst revisions were mixed. HC Wainwright slightly reduced its FY2027 loss estimate to $3.36 per share from $3.27, but improved forecasts for later years as it incorporated the potential impact of Zenkuda.
Negative Sentiment: Investors face substantial execution and financing risks. Kodiak has no current revenue and continues to burn cash, making a future share offering possible. Unusually high put-option buying also suggests some traders are positioning for volatility or a pullback after the dramatic rally. Kodiak valuation and financing risks article

About Kodiak Sciences

(Get Free Report)

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.